Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History GOVX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics GOVX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

GeoVax Labs Inc

GOVX
Current price
0.77 USD +0.034 USD (+4.71%)
Last closed 0.73 USD
ISIN US3736786068
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 19 247 094 USD
Yield for 12 month -71.35 %
1Y
3Y
5Y
10Y
15Y
GOVX
21.11.2021 - 28.11.2021

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. Address: 1900 Lake Park Drive, Smyrna, GA, United States, 30080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

11.38 USD

P/E Ratio

Dividend Yield

Financials GOVX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures GOVX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+3 954 576 USD

Last Year

Current Quarter

+1 636 863 USD

Last Quarter

+864 415 USD

Current Year

+3 859 208 USD

Last Year

-20 720 766 USD

Current Quarter

+1 636 863 USD

Last Quarter

+842 774 USD
EBITDA -24 566 646 USD
Operating Margin TTM -330.18 %
Price to Earnings
Return On Assets TTM -915.19 %
PEG Ratio
Return On Equity TTM -78 814.56 %
Wall Street Target Price 11.38 USD
Revenue TTM 5 591 576 USD
Book Value 0.0010 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -19 051 026 USD
Earnings per share -2.80 USD
Diluted Eps TTM -2.80 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation GOVX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 10.63
Enterprise Value Revenue 2.85
Price Sales TTM 3.44
Enterprise Value EBITDA 0.10
Price Book MRQ 2.20

Technical Indicators GOVX

For 52 Weeks

0.43 USD 11.18 USD
50 Day MA 0.91 USD
Shares Short Prior Month 538 737
200 Day MA 1.63 USD
Short Ratio 1.54
Shares Short 3 006 357
Short Percent 3.41 %